Patents by Inventor Robert Francis Kaiko
Robert Francis Kaiko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130012533Abstract: A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises wet granulating at least one hydrophilic or hydrophobic polymer, preferably a hydroxyalkyl cellulose or an alkyl cellulose, with oxycodone or a salt thereof to form a controlled-release matrix. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration.Type: ApplicationFiled: September 5, 2012Publication date: January 10, 2013Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Publication number: 20130011543Abstract: A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration.Type: ApplicationFiled: September 5, 2012Publication date: January 10, 2013Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Publication number: 20100092570Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: October 15, 2009Publication date: April 15, 2010Inventors: Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko
-
Publication number: 20100034876Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: October 15, 2009Publication date: February 11, 2010Inventors: Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko
-
Publication number: 20040185098Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 2.Type: ApplicationFiled: March 24, 2004Publication date: September 23, 2004Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Publication number: 20040105887Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: November 12, 2003Publication date: June 3, 2004Inventors: Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko
-
Publication number: 20040096500Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “g12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: November 12, 2003Publication date: May 20, 2004Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Publication number: 20030099704Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from-about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour)- administration through steady-state conditions.Type: ApplicationFiled: June 5, 2002Publication date: May 29, 2003Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Publication number: 20020018810Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: August 20, 2001Publication date: February 14, 2002Inventors: Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko
-
Publication number: 20010008639Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions.Type: ApplicationFiled: February 16, 2001Publication date: July 19, 2001Inventors: Benjamin Oshlack, John Joseph Minogue, Mark Chasin, Robert Francis Kaiko
-
Patent number: 5656295Abstract: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions.Type: GrantFiled: March 19, 1996Date of Patent: August 12, 1997Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko